| Autor: |
Subrata Kumar Palo, Matrujyoti Pattnaik, Nityananda Mondal, Kumudini Panigrahi, Hari Ram Choudhary, Dipti Pattnaik, Susmita Behera, Srikanta Kanungo, Subrat Kumar Pradhan, Prasanta Kumar Choudhary, Sanjeeb Kumar Mishra, Jaya Singh Kshatri, Girish Chandra Dash, Subrat Kumar Sahoo, Usha Kiran Rout, Nihar Ranjan Sahoo, Adyasha Mishra, Sunil K. Raghav, Rashmi Ranjan Nanda, Narayan Chandra Mishra, Debdutta Bhattacharya, Sreeparna Podder, Debaprasad Parai, Sanghamitra Pati |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
Rationale: Vaccine rollout in India was initiated in mid-January, 2021 and is supposed to be the only antidote against SARS-CoV-2 as of now.Objectives: To study the dynamicity of vaccine-induced IgG antibody against SARS-CoV-2.Methodology: The present cross-sectional cohort study was undertaken to determine IgG antibody among health care workers with completed dose of either Covaxin or Covishield and were followed for 24 weeks after first dose of either vaccine to record the periodic changes in titre, concentration, clinical growth and persistence of vaccine-induced SARS-CoV-2 antibodies.Results: Serum samples were collected from 614 participants during each follow-up and tested them in two CLIA-based platforms for testing SARS-CoV-2 antibodies both qualitatively and quantitatively. Among these participants, 308 (50.2%) were Covishield recipient and rest 306 (49.8%) took Covaxin. A total of 81 breakthrough cases was recorded among the cohort participants for whom infection post vaccination acted as booster. The rest 533 heath care workers without any history of post-vaccination infection showed significant antibody waning either from T3 (Covaxin recipient) or T4 (Covishield recipient).Conclusion: The clinical implications of waning antibody levels post vaccination are not well understood, and it remains crucial to establish S-antibody thresholds associated with protection against clinical outcomes. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
